2018
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 693-702. PMID: 29891520, DOI: 10.6004/jnccn.2018.0056.Peer-Reviewed Original ResearchConceptsPrimary neuroendocrine tumorNeuroendocrine tumorsAdrenal tumorsManagement of NETsLocoregional advanced diseaseNCCN Guidelines InsightsAdrenal gland tumorsAdvanced diseaseNCCN guidelinesAdult patientsDistant metastasisGastrointestinal tractGland tumorsTumorsNeuroendocrineManagement optionsGuidelinesPatientsPheochromocytomaMetastasisParagangliomaDiseaseTract
2008
Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer
Khan SA, Idrees K, Forslund A, Zeng Z, Rosenberg S, Pincas H, Barany F, Offit K, LaQuaglia MP, Paty PB. Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer. Journal Of Surgical Oncology 2008, 97: 621-625. PMID: 18381604, PMCID: PMC4381874, DOI: 10.1002/jso.20996.Peer-Reviewed Original ResearchConceptsEarly-onset colorectal cancerOnset colorectal cancerColorectal cancerMDM2 SNP309Age 30Germline variantsLi-Fraumeni kindredsP53 genePeripheral blood leukocytesNormal control populationP53 pathway genesFrequency of polymorphismsGermline TP53Blood leukocytesRare diseaseSNP309Control populationTissue availabilityPatientsConstitutional mutationsDisease susceptibilityCancerP53DiseaseGenetic variants